Advisor Group Inc. Buys 15,358 Shares of Tandem Diabetes Care Inc (NASDAQ:TNDM)

Advisor Group Inc. raised its stake in shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) by 653.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,709 shares of the medical device company’s stock after buying an additional 15,358 shares during the quarter. Advisor Group Inc.’s holdings in Tandem Diabetes Care were worth $1,124,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Bank of America Corp DE raised its stake in Tandem Diabetes Care by 250.1% during the fourth quarter. Bank of America Corp DE now owns 121,451 shares of the medical device company’s stock valued at $4,613,000 after buying an additional 86,763 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Tandem Diabetes Care by 2.3% in the 4th quarter. California State Teachers Retirement System now owns 79,809 shares of the medical device company’s stock worth $3,030,000 after purchasing an additional 1,800 shares in the last quarter. Columbus Circle Investors increased its holdings in shares of Tandem Diabetes Care by 1,896.9% in the 4th quarter. Columbus Circle Investors now owns 848,842 shares of the medical device company’s stock worth $32,231,000 after purchasing an additional 806,335 shares in the last quarter. Orbimed Advisors LLC increased its holdings in shares of Tandem Diabetes Care by 32.7% in the 4th quarter. Orbimed Advisors LLC now owns 948,000 shares of the medical device company’s stock worth $35,996,000 after purchasing an additional 233,500 shares in the last quarter. Finally, Tarbox Family Office Inc. increased its holdings in shares of Tandem Diabetes Care by 11.6% in the 1st quarter. Tarbox Family Office Inc. now owns 5,780 shares of the medical device company’s stock worth $367,000 after purchasing an additional 600 shares in the last quarter. Institutional investors and hedge funds own 80.49% of the company’s stock.

Shares of TNDM opened at $70.07 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.43 and a quick ratio of 2.13. Tandem Diabetes Care Inc has a one year low of $15.50 and a one year high of $74.81. The firm has a market capitalization of $4.16 billion, a P/E ratio of -27.48 and a beta of 0.51.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Tuesday, April 30th. The medical device company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.10). Tandem Diabetes Care had a negative return on equity of 40.76% and a negative net margin of 50.73%. The firm had revenue of $66.00 million during the quarter, compared to the consensus estimate of $47.55 million. During the same period in the previous year, the firm earned ($1.82) EPS. The business’s revenue was up 141.9% on a year-over-year basis. Equities research analysts predict that Tandem Diabetes Care Inc will post -0.81 EPS for the current fiscal year.

In related news, EVP Brian B. Hansen sold 10,000 shares of Tandem Diabetes Care stock in a transaction on Friday, March 15th. The stock was sold at an average price of $72.00, for a total value of $720,000.00. Following the completion of the sale, the executive vice president now owns 11,381 shares of the company’s stock, valued at $819,432. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David B. Berger sold 2,000 shares of Tandem Diabetes Care stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $62.60, for a total value of $125,200.00. Following the completion of the sale, the executive vice president now directly owns 3,765 shares of the company’s stock, valued at approximately $235,689. The disclosure for this sale can be found here. Insiders sold 53,000 shares of company stock valued at $3,505,580 in the last ninety days. 6.90% of the stock is currently owned by corporate insiders.

A number of research firms have commented on TNDM. BidaskClub raised Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a report on Wednesday, June 5th. Bank of America reissued a “neutral” rating and issued a $65.00 target price on shares of Tandem Diabetes Care in a report on Friday, May 17th. ValuEngine raised Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 15th. Svb Leerink began coverage on Tandem Diabetes Care in a report on Monday, May 13th. They issued an “outperform” rating and a $83.00 target price for the company. Finally, Leerink Swann began coverage on Tandem Diabetes Care in a report on Monday, May 13th. They issued an “outperform” rating and a $83.00 target price for the company. Four analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $68.13.

ILLEGAL ACTIVITY NOTICE: “Advisor Group Inc. Buys 15,358 Shares of Tandem Diabetes Care Inc (NASDAQ:TNDM)” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2019/06/13/advisor-group-inc-buys-15358-shares-of-tandem-diabetes-care-inc-nasdaqtndm.html.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Article: How does a security become overbought?

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care Inc (NASDAQ:TNDM).

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply